Randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of desmoteplase in acute ischemic stroke
09/01/2009 - 12/31/2014 (PI)Lundbeck, Inc.
A Phase 2, Randomized, Double Blind Placebo Controlled Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of PF-04360365 (Ponezumab)
10/21/2013 - 11/30/2014 (PI)Pfizer, Inc.
Personnel Agreement for Research Services of Ethan Treglia
01/01/2011 - 09/30/2012 (PI)VA Boston Healthcare System
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic D
05/01/2008 - 04/30/2012 (PI)Schering-Plough Research Institute
12/01/2009 - 01/31/2012 (Subcontract PI)University of British Columbia NIH NINDS
PREDICT (Predicting hEmatoma growth anD outcome in Intracerebral hemorrhage using contrast bolus CT) study
11/01/2009 - 10/30/2010 (PI)University of Calgary
PRoFESS- Prevention Regimen for Effectively Avoiding Second Strokes: A Double-Blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel and Aspirin, With and Without Micardis
09/01/2003 - 08/31/2007 (PI)Boehringer Ingelheim Pharmaceuticals
DIAS 2: Desmoteplase (INN) In Acute Ischemic Stroke: Phase III
05/17/2005 - 12/31/2006 (PI)Forest Laboratories, Inc./Forest Research Institute
Management of Atherothrombosis with Clopidogrel in High Risk Patients with Recent Transient Ischemic of Ischemic Stroke
09/01/2001 - 08/31/2003 (PI)Parexel Sanofi Synthelabo
Epidemiologic Study of Acute Ischemic Stroke (ESIS)
09/22/2000 - 07/31/2003 (PI)Genentech, Inc.
Showing 10 of 12 results.
Show All Results